伤口愈合的基于黄胺的治疗方法的最新进展:聚焦聚合物和混合输送系统
Gajendra Singh Thakur1, Vijay Pratap Ahirwar1, Harshita Singhai1
1Department of Pharmaceutical Science, Dr. Harisingh Gour Vishwavidyalaya (A Central University), Sagar, Madhya Pradesh, 470003, India.
Current pharmaceutical design
|March 16, 2026
概括
天然的黄胺在伤口愈合方面表现有前途,但交付方面的挑战阻碍了它们的使用. 聚合物系统增强了黄类物质的输送,改善了组织再生和临床结果,以改善伤口修复.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 伤口愈合涉及复杂的阶段:静血,炎症,增殖和重塑.
- 慢性炎症,氧化应激和感染阻碍了有效的组织再生.
- 自然的黄类化合物具有抗氧化,抗炎和抗微生物特性,有利于伤口修复.
研究的目的:
- 审查在伤口管理中的天然黄类物质的基于聚合物的输送系统.
- 讨论这些系统的特性,选择标准和机制.
- 突出它们在克服药理动力学障碍和增强治疗潜力的作用.
主要方法:
- 关于聚合物和混合物输送系统的综合文献综述.
- 分析黄酸性质及其对伤口愈合阶段的影响.
- 对聚合物系统特征 (水凝,纳米纤维,纳米颗粒) 进行药物封装,释放和稳定性的评估.
主要成果:
- 聚合物系统提高了黄类的溶解性,生物可用性和稳定性.
- 这些系统有助于持续释放和黄素的有针对性的输送.
- 黄素和聚合物载体的协同作用增强了组织再生和伤口愈合.
结论:
- 基于聚合物的输送系统对于优化伤口管理中的黄类药物疗效至关重要.
- 这些先进的系统克服了药物动力学限制,为改善临床结果铺平了道路.
- 开发具有聚合物载体的多功能平台对再生医学具有重大前景.
相关概念视频
Site-Targeted Drug Delivery Systems: Polymeric Carriers
82
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
82
Modified-Release Drug Delivery Systems: Stimuli-Activated
74
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
74
Modified-Release Drug Delivery Systems: Classification
192
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
192
Modified-Release Drug Delivery Systems: Site-Targeted
73
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
73
Modified-Release Drug Delivery Systems: Rate-Programmed II
72
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
72
Drug Delivery Systems: Different Types
176
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
176


